Literature DB >> 15695960

Placebo controlled trial of methotrexate in systemic sclerosis.

S N Das1, M R Alam, N Islam, M H Rahman, S R Sutradhar, S Rahman, G K Khan, A Rahim, S A Haq.   

Abstract

Eighteen adult patients of systemic sclerosis were included in this prospective study from Rheumatology Clinic of Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka during the period of July 1997 to December 1999 to observe the effectiveness of treatment with methotrexate (MTX) versus placebo. Among the eighteen patients 9 patients were randomly assigned to MTX and 9 to placebo therapy. Nine patients were dropped out (6 in placebo and 3 in the MTX group), because of toxicity and non-compliance. Clinical improvement following treatment was observed in 33.33% of the patient in MTX group but none in placebo group, but this difference was not statistically significant. Anorexia, nausea and occasional vomiting were common side effects in MTX group and subsided in most cases with the passage of time despite the continuation of therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15695960

Source DB:  PubMed          Journal:  Mymensingh Med J        ISSN: 1022-4742


  6 in total

Review 1.  Recent advances in the treatment of systemic sclerosis.

Authors:  Vasiliki Kalliopi K Bournia; Panayiotis G Vlachoyiannopoulos; Carlo Selmi; Haralampos M Moutsopoulos; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

Review 2.  [Therapeutic management in early disease stages of systemic sclerosis : early diagnosis - early symptoms - early problems].

Authors:  M Frerix; F M P Meier; W Hermann; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2013-12       Impact factor: 1.372

3.  An Update on the Treatment of the Cutaneous Manifestations of Systemic Sclerosis: The Dermatologist's Point of View.

Authors:  Magalys Vitiello; Adriana Abuchar; Néstor Santana; Luis Dehesa; Francisco A Kerdel
Journal:  J Clin Aesthet Dermatol       Date:  2012-07

Review 4.  Pharmacotherapy of systemic sclerosis.

Authors:  Arnold E Postlethwaite; L Jeff Harris; Syed H Raza; Swapna Kodura; Titilola Akhigbe
Journal:  Expert Opin Pharmacother       Date:  2010-04       Impact factor: 3.889

Review 5.  Scleroderma therapy: clinical overview of current trends and future perspective.

Authors:  Afsha A Topal; Rachita S Dhurat
Journal:  Rheumatol Int       Date:  2012-08-03       Impact factor: 2.631

6.  Defining the optimal disease duration of early diffuse systemic sclerosis for clinical trial design.

Authors:  Robyn T Domsic; Shiyao Gao; Maureen Laffoon; Steven Wisniewski; Yuqing Zhang; Virginia Steen; Robert Lafyatis; Thomas A Medsger
Journal:  Rheumatology (Oxford)       Date:  2021-10-02       Impact factor: 7.580

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.